Memantine in Bipolar Patients With Alcoholism
Using Memantine in Treating Bipolar Disorder Comorbid With Alcoholism
Sponsor: National Cheng-Kung University Hospital
Listed as NCT03043001, this PHASE3 trial focuses on AOD Effects and Consequences and remains ongoing. Sponsored by National Cheng-Kung University Hospital, it has been updated 8 times since 2014, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
8 versions recorded-
Dec 2025 — Present [monthly]
Unknown PHASE3
-
Sep 2025 — Dec 2025 [monthly]
Unknown PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Unknown PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE3
Status: Unknown Status → Unknown
-
Jan 2021 — Jul 2024 [monthly]
Unknown Status PHASE3
▶ Show 3 earlier versions
-
Oct 2019 — Jan 2021 [monthly]
Unknown Status PHASE3
Status: Enrolling By Invitation → Unknown Status
-
Jun 2018 — Oct 2019 [monthly]
Enrolling By Invitation PHASE3
-
Feb 2017 — Jun 2018 [monthly]
Enrolling By Invitation PHASE3
First recorded
Jan 2014
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- National Cheng-Kung University Hospital
For direct contact, visit the study record on ClinicalTrials.gov .